Product
Centhaquine
Aliases
PMZ-2010
3 clinical trials
2 indications
Indication
Hypovolemic ShockIndication
COVID-19 ARDSClinical trial
A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of ShockStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Multicentric Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Centhaquine as an Adjuvant to the Standard of Care in COVID-19 Patients With Moderate to Severe Acute Respiratory Distress SyndromeStatus: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Multi-Centric, Randomized, Double-Blind, Placebo-controlled, Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent to be Used as an Adjuvant to Standard Treatment of Hypovolemic ShockStatus: Not yet recruiting, Estimated PCD: 2025-10-01